Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(25%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
25%
Ph phase_3
2
50%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
2(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(2)
Other(1)

Detailed Status

Completed2
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (33.3%)
Phase 32 (66.7%)

Trials by Status

recruiting125%
unknown125%
completed250%

Recent Activity

1 active trials
Showing 4 of 4
recruitingphase_3

Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina

NCT03789552
completedphase_3

Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)

NCT04993729
unknown

Expanded Access to T89 for Treatment Use in Intermediate-size Patients Population With COVID-19

NCT04646031
completedphase_2

Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)

NCT03552263

Clinical Trials (4)

Showing 4 of 4 trials
NCT03789552Phase 3

Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina

Recruiting
NCT04993729Phase 3

Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)

Completed
NCT04646031

Expanded Access to T89 for Treatment Use in Intermediate-size Patients Population With COVID-19

Unknown
NCT03552263Phase 2

Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4